Search results for "antineoplastic"

showing 10 items of 2217 documents

Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin

2021

Nanoparticles (NPs) have emerged as a potential tool to improve cancer treatment. Among the proposed uses in imaging and therapy, their use as a drug delivery scaffold has been extensively highlighted. However, there are still some controversial points which need a deeper understanding before clinical application can occur. Here the use of gold nanoparticles (AuNPs) to detoxify the antitumoral agent cisplatin, linked to a nanoparticle via a pH-sensitive coordination bond for endosomal release, is presented. The NP conjugate design has important effects on pharmacokinetics, conjugate evolution and biodistribution and results in an absence of observed toxicity. Besides, AuNPs present unique o…

Time FactorsCancer TreatmentMetal Nanoparticleslcsh:MedicinePharmacologyMiceNanotechnologyTissue Distributionlcsh:Sciencemedia_commonDrug DistributionDrug CarriersMultidisciplinaryChemistryDNA NeoplasmOrgan SizeHydrogen-Ion ConcentrationEndocytosisOncologyColloidal goldDrug deliveryInactivation MetabolicMedicinemedicine.drugResearch ArticleBiotechnologyDrugBiodistributionDrugs and Devicesmedia_common.quotation_subjectMaterials ScienceAntineoplastic AgentsMaterial by AttributePharmacokineticsCell Line TumormedicineAnimalsHumansPharmacokineticsBiologyNanomaterialsCisplatinUnited States Food and Drug Administrationlcsh:RChemotherapy and Drug TreatmentUnited StatesBionanotechnologylcsh:QGoldNanocarriersCisplatinConjugate
researchProduct

SYNTHESIS, CHARACTERIZATION AND IN VITRO CYTOTOXICITY STUDIES OF A MACROMOLECULAR CONJUGATE OF PACLITAXEL BEARING OXYTOCIN AS TARGETING MOIETY.

2007

The present study describes the experimental synthetic procedure and the characterization of a new polyaspartamide macromolecular prodrug of paclitaxel, bearing oxytocin residues as targeting moieties. In vitro stability studies of bioconjugate, performed in media mimicking biological fluids (buffer solutions at pH 7.4 and 5.5) and in human plasma, evidenced the high stability of the targeting portion (oxytocin)-polymer linkage and the ability of this conjugate to release linked paclitaxel in a prolonged way in plasma. Moreover, preliminary in vitro antiproliferative studies, carried out on MCF-7 cells, that are oxytocin receptor positive cells, showed that the polymeric conjugate has the s…

Time FactorsChemistry PharmaceuticalDrug CompoundingpolyaspartamidePharmaceutical ScienceBreast NeoplasmsPolyethylene Glycolschemistry.chemical_compoundpaclitaxelDrug StabilityCell Line TumoroxytocinHumansMoietyProdrugsbioconjugateCytotoxicityCell ProliferationDrug CarriersDose-Response Relationship DrugMolecular StructureHydrolysisdrug targetingGeneral MedicineHydrogen-Ion ConcentrationAntineoplastic Agents PhytogenicOxytocin receptorIn vitroSolubilityPaclitaxelchemistryBiochemistryTargeted drug deliveryReceptors OxytocinDelayed-Action PreparationsFemalePeptidesDrug carrierBiotechnologyConjugate
researchProduct

Stability of irinotecan-loaded drug eluting beads (DC BeadTM) used for transarterial chemoembolization

2009

Purpose. The aim of this study was to determine the loading efficiency, physicochemical stability, and release of irinotecan-loaded DC BeadsTM (bead size 100—300 μm, 300—500 μm) before and after mixing with nonionic contrast medium (Accupaque® 300, Imeron® 300, Ultravist ® 300) during a prolonged period of time (28 days) when stored at room temperature or refrigerated. Methods. DC Beads TM were loaded with 50 mg irinotecan (Campto®) per milliliter beads in a 2 h loading period. Drug loading efficiency and stability were determined by measuring the irinotecan concentration in the excess solution. A free-flowing in vitro elution method for a period of 2 h and phosphate buffered solution (PBS…

Time FactorsDrug CompoundingDrug StorageContrast MediaBeadIrinotecanchemistry.chemical_compoundDrug Delivery SystemsDrug StabilityIntra arterialInfusions Intra-ArterialMedicinePharmacology (medical)Chemoembolization TherapeuticParticle SizeSolubilityChromatography High Pressure LiquidChromatographyDrug eluting beadsbusiness.industryElutionTemperaturePhosphateAntineoplastic Agents PhytogenicMicrospheresIrinotecanSolubilityOncologychemistryvisual_artvisual_art.visual_art_mediumCamptothecinParticle sizebusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells

2015

Osteosarcoma (OS), an aggressive highly invasive and metastatic bone-malignancy, shows therapy resistance and recurrence, two features that likely depend on cancer stem cells (CSCs), which hold both self-renewing and malignant potential. So, effective anticancer therapies against OS should specifically target and destroy CSCs. We previously found that the let-7d microRNA was downregulated in the 3AB-OS-CSCs, derived from the human OS-MG63 cells. Here, we aimed to assess whether let-7d modulation affected tumorigenic and stemness properties of these OS-CSCs. We found that let-7d-overexpression reduced cell proliferation by decreasing CCND2 and E2F2 cell-cycle-activators and increasing p21 an…

Time FactorsEpithelial-Mesenchymal TransitionTime FactorTranscription FactorPhysiologyClinical BiochemistryDrug ResistanceAntineoplastic AgentsApoptosisBone NeoplasmsCell Cycle ProteinsBone NeoplasmTransfectionCell LineAntineoplastic AgentCell MovementCell Line TumorCell Cycle ProteinHumansNeoplasm InvasivenessCell Self RenewalAntineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line Tumor; Cell Movement; Cell Self Renewal; Drug Resistance Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Osteosarcoma; Phenotype; Signal Transduction; Time Factors; Transcription Factors; Transfection; Physiology; Medicine (all); Clinical Biochemistry; Cell BiologyNeoplasm InvasiveneNeoplasticOsteosarcomaTumorApoptosis Regulatory ProteinMedicine (all)Cell CycleApoptosiMicroRNACell BiologyGene Expression Regulation NeoplasticMicroRNAsPhenotypeGene Expression RegulationDrug Resistance NeoplasmNeoplastic Stem CellsNeoplasmNeoplastic Stem CellApoptosis Regulatory ProteinsTranscription FactorsHumanSignal Transduction
researchProduct

Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.

2009

Paclitaxel (PTX) and beta-lapachone (LPC) are naturally occurring compounds that have shown a large spectrum of anticancer activity. In this article we show for the first time that PTX/LPC combination induces potent synergistic apoptotic effects in human retinoblastoma Y79 cells. Combination of suboptimal doses of PTX (0.3 nM) and LPC (1.5 microM) caused biochemical and morphological signs of apoptosis at 48 h of treatment. These effects were accompanied by potent lowering in inhibitor of apoptosis proteins and by activation of Bid and caspases 3 and 6 with lamin B and PARP breakdown. PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM…

Time FactorsPhysiologyClinical BiochemistryApoptosisInhibitor of Apoptosis ProteinsWortmanninchemistry.chemical_compoundSettore BIO/10 - BiochimicaAntineoplastic Combined Chemotherapy ProtocolsPhosphorylationCaspasebiologyCaspase 6Lamin Type BCaspase 3Protein StabilityRetinoblastomaDrug SynergismProto-Oncogene Proteins c-mdm2TransfectionBiochemistrylipids (amino acids peptides and proteins)Poly(ADP-ribose) PolymerasesWortmanninBH3 Interacting Domain Death Agonist Proteinretinoblastoma survival factors apoptosisPaclitaxelCell SurvivalPoly ADP ribose polymeraseActive Transport Cell NucleusDown-RegulationInhibitor of apoptosisTransfectionCell Line TumorHumansProtein kinase BProtein Kinase InhibitorsCell NucleusDose-Response Relationship DrugCell BiologyAntineoplastic Agents PhytogenicAndrostadieneschemistryCell cultureApoptosisbiology.proteinCancer researchTumor Suppressor Protein p53Proto-Oncogene Proteins c-aktNaphthoquinonesJournal of cellular physiology
researchProduct

Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions

2011

Purpose: The aim of this study was to investigate the physicochemical stability of clofarabine (CAFdA) injection concentrate and ready-to-use CAFdA infusion solutions over a prolonged period of 28 days. Methods: To determine the stability of CAFdA infusion solutions, the injection concentrate (Evoltra®, 1 mg/mL, Genzyme) was diluted either with 0.9% sodium chloride or 5% glucose infusion solution. The resulting concentrations of 0.2 mg/mL or 0.6 mg/mL, respectively, were chosen to represent the lower and upper limit of the ordinary concentration range. Test solutions were stored under refrigeration (2–8°C) or at room temperature either light protected or exposed to light. CAFdA concentrati…

Time FactorsStability studyDrug StorageSodiumchemistry.chemical_elementAntineoplastic AgentsInjection concentratechemistry.chemical_compoundGlucose infusionDrug StabilitymedicineClofarabinePharmacology (medical)Clofarabine InjectionInfusions IntravenousChromatography High Pressure LiquidChromatographyAdenine Nucleotidesbusiness.industryReproducibility of ResultsPolyethylenePharmaceutical SolutionsPolyvinyl chlorideOncologychemistryArabinonucleosidesbusinessClofarabinemedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Acrylamide catalytically inhibits topoisomerase II in V79 cells.

2010

The vinyl monomer acrylamide is characterized by the presence of an alpha,beta-unsaturated carbonyl group that makes it reactive towards thiol, hydroxyl or amino groups and towards the nucleophilic centers in DNA. The ability of acrylamide to chemically modify protein thiols has prompted us to consider topoisomerase II as one possible target of acrylamide, since agents targeting protein sulfhydryl groups act as either catalytic inhibitors or poisons of topoisomerase II. Nuclear extracts from V79 Chinese hamster cells incubated with acrylamide reduced topoisomerase II activity as inferred by an inability to convert kinetoplast DNA to the decatenated form. Nuclear extracts incubated with acry…

ToxicologyCleavage (embryo)Cell LineColony-Forming Units AssayV79 cellchemistry.chemical_compoundCell Line TumorCricetinaemedicineAnimalsTopoisomerase II InhibitorsDNA CleavageEtoposideEtoposideNucleic Acid Synthesis Inhibitorschemistry.chemical_classificationCell NucleusAcrylamidebiologyTopoisomeraseDNA KinetoplastGeneral MedicineTopoisomerase IIAntineoplastic Agents PhytogenicSettore BIO/18 - GeneticaEnzymechemistryBiochemistryKinetoplastAcrylamidebiology.proteinTopoisomerase-II InhibitorDNAmedicine.drugToxicology in vitro : an international journal published in association with BIBRA
researchProduct

Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells

2011

Aberrant inactivation of tumor suppressor genes by promoter hypermethylation has been recognized as a crucial step of tumor development and is related to aggressiveness and therapy resistance. To identify potential novel treatment strategies, we evaluated pharmacological genome demethylation for the increase of irradiation treatment effectiveness in head and neck squamous cell carcinoma (HNSCC) in this in vitro study. HNSCC cells were cultured with 2 different concentrations of 5-azacytidine (5-Aza) for 72 h, followed by a single fraction irradiation with 4 or 50 Gy, respectively. To show successful genome demethylation, the methylation status of the tumor suppressor gene hic1 (hypermethyla…

Transcriptional ActivationAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingBiologyRadiation ToleranceCell Line TumorGeneticsmedicineHumansRadiosensitivityPromoter Regions GeneticDemethylationOncogeneSquamous Cell Carcinoma of Head and NeckGeneral MedicineDNA MethylationCell cyclemedicine.diseaseHead and neck squamous-cell carcinomaSquamous carcinomaGene Expression Regulation NeoplasticHead and Neck NeoplasmsAzacitidineCarcinoma Squamous CellCancer researchInternational Journal of Molecular Medicine
researchProduct

Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptos…

2001

In a search for retinoic acid (RA) receptor ligands endowed with potent apoptotic activity, a series of novel arotinoids were prepared. Because the stereochemistry of the C9-alkenyl portion of natural 9-cis-RA and the olefinic moiety of the previously synthesized isoxazole retinoid 4 seems to have particular importance for their apoptotic activity, novel retinoid analogues with a restricted or, vice versa, a larger flexibility in this region were designed and prepared. The new compounds were evaluated in vitro for their ability to activate natural retinoid receptors and for their differentiation-inducing activity. Cytotoxic and apoptotic activities were, in addition, evaluated. In general, …

Transcriptional ActivationProgrammed cell deathTetrahydronaphthalenesmedicine.drug_classReceptors Retinoic AcidRetinoic acidAntineoplastic AgentsApoptosisBenzoateschemistry.chemical_compoundInhibitory Concentration 50RetinoidsDrug DiscoverymedicineTumor Cells CulturedHumansRetinoidIsoxazoleCytotoxicityReceptorCell DifferentiationIsoxazolesIn vitroDrug Resistance MultipleBiochemistrychemistryApoptosisDrug Resistance NeoplasmMolecular MedicineDrug Screening Assays AntitumorCell DivisionJournal of medicinal chemistry
researchProduct

Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

2013

BACKGROUND: The Human Epidermal Growth Factor Receptor 2 (HER-2), overexpressed in 25-30% of breast carcinomas (BC), is the therapeutic target for trastuzumab, a recombinant humanized monoclonal antibody. The initial response to trastuzumab is often followed by drug-insensitivity within one year. Several hypotheses have been raised to explain this event, but the mechanisms behind the responses to trastuzumab are still unclear. Aim: To study the effects of short and prolonged trastuzumab treatment on the proteomic profiles of HER-2-overexpressing SKBR-3 BC cells. MATERIALS AND METHODS: Cells were treated with trastuzumab to obtain sensitive and resistant clones. The drug effects were evaluat…

Trastuzumab Herceptin(R) Breast Cancer ProteomicsBlotting WesternAntineoplastic AgentsBreast NeoplasmsTrastuzumabAntibodies Monoclonal HumanizedMass SpectrometrySettore BIO/13 - Biologia ApplicataDrug Resistance NeoplasmCell Line TumorHumansElectrophoresis Gel Two-DimensionalFemaleSettore BIO/06 - Anatomia Comparata E CitologiaTranscriptomeCell ProliferationAnticancer research
researchProduct